The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned...

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Methamphetamine (METH) dependence is a significant public health issue.
• Monoamine transporters, particularly the serotonin transporter (SERT), are key targets of METH.
• Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine have shown potential in reducing METH's rewarding effects.

Purpose of the Study:

• To investigate the efficacy of additional SSRIs, paroxetine and fluvoxamine, in reducing METH-induced conditioned place preference (CPP) in mice.
• To explore the role of SERT inhibition and other molecular targets in mediating the effects of SSRIs on METH reward.

Main Methods:

• C57BL/6J mice were used to assess METH CPP.
• Mice were pretreated with paroxetine (20 mg/kg) or fluvoxamine (100 mg/kg) before METH administration.
• CPP was measured to quantify the rewarding effects of METH.

Main Results:

• Paroxetine pretreatment significantly abolished METH CPP.
• Fluvoxamine pretreatment failed to inhibit METH CPP.
• These findings indicate a differential effect of SSRIs on METH reward.

Conclusions:

• Paroxetine may serve as a potential therapeutic agent for treating METH dependence.
• The results suggest that molecular targets other than SERT, possibly G protein-activated inwardly rectifying K+ (GIRK) channels, are involved in the METH-reducing effects of paroxetine and fluoxetine.